Well there is one patient so far with a very aggressive cancer type and out of options, who has now been cancer free for 2 years.
I take it you mean that the response rate will be low. Maybe, we'll see.
But even a drug with excellent safety and low-moderate complete response rate in refractory cholangiocarcinoma patients would be highly marketable and clinically relevant.
IMU Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)